Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Oct;59(10):3504–3510. doi: 10.1128/iai.59.10.3504-3510.1991

Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.

C C Peeters 1, A M Tenbergen-Meekes 1, J T Poolman 1, M Beurret 1, B J Zegers 1, G T Rijkers 1
PMCID: PMC258913  PMID: 1894357

Abstract

Previous studies with saccharide-protein conjugates have demonstrated that antibody responses to the saccharide can be improved by the preexistence of carrier immunity. Here we report that prior exposure to the carrier protein can either enhance or suppress antibody response to polysaccharides administered in saccharide-protein conjugates. A dose-dependent role for carrier priming in the antisaccharide antibody response to three saccharide-protein conjugate vaccines, i.e., a Streptococcus pneumoniae type 4 polysaccharide-tetanus toxoid (TT) conjugate (PS4TT), a Neisseria meningitidis group C polysaccharide-TT conjugate (MenCTT), and a N. meningitidis group C oligosaccharide-diphtheria mutant toxin conjugate (MenCCRM), was investigated. The results showed that an increase in the antipolysaccharide antibody response could be obtained for both PS4TT and MenCTT but not for MenCCRM with low-dose carrier priming (0.025 to 0.25 microgram). However, suppression of the antipolysaccharide antibody response was observed with the PS4TT and MenCTT vaccines with high-dose (25-micrograms) carrier priming. There was no suppression effect with MenCCRM. The increase in the antipolysaccharide antibody response was shown to be restricted to the immunoglobulin G1 (IgG1) subclass, whereas suppression with high-dose carrier priming affected all antipolysaccharide subclass antibodies induced by PS4TT (IgG1, IgG2b, and IgG3) and only two of the four subclass antibodies induced by MenCTT (IgG2a and IgG2b). The increase in the antipolysaccharide antibody response was also present at the antipolysaccharide IgM antibody level but was not observed at the anti-carrier IgG antibody level.

Full text

PDF
3504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P. W., Pichichero M. E., Insel R. A., Betts R., Eby R., Smith D. H. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol. 1986 Aug 15;137(4):1181–1186. [PubMed] [Google Scholar]
  2. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun. 1983 Jan;39(1):233–238. doi: 10.1128/iai.39.1.233-238.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barington T., Kristensen K., Henrichsen J., Heilmann C. Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 1991 Mar;59(3):1057–1064. doi: 10.1128/iai.59.3.1057-1064.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beuvery E. C., van Rossum F., Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun. 1982 Jul;37(1):15–22. doi: 10.1128/iai.37.1.15-22.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bixler G. S., Jr, Pillai S. The cellular basis of the immune response to conjugate vaccines. Contrib Microbiol Immunol. 1989;10:18–47. [PubMed] [Google Scholar]
  6. Chu C., Schneerson R., Robbins J. B., Rastogi S. C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun. 1983 Apr;40(1):245–256. doi: 10.1128/iai.40.1.245-256.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Sadoff J. C., Fürer E., Germanier R. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J Infect Dis. 1986 Oct;154(4):682–688. doi: 10.1093/infdis/154.4.682. [DOI] [PubMed] [Google Scholar]
  8. Di John D., Wasserman S. S., Torres J. R., Cortesia M. J., Murillo J., Losonsky G. A., Herrington D. A., Stürcher D., Levine M. M. Effect of priming with carrier on response to conjugate vaccine. Lancet. 1989 Dec 16;2(8677):1415–1418. doi: 10.1016/s0140-6736(89)92033-3. [DOI] [PubMed] [Google Scholar]
  9. Einhorn M. S., Weinberg G. A., Anderson E. L., Granoff P. D., Granoff D. M. Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet. 1986 Aug 9;2(8502):299–302. doi: 10.1016/s0140-6736(86)90001-2. [DOI] [PubMed] [Google Scholar]
  10. Etlinger H. M., Felix A. M., Gillessen D., Heimer E. P., Just M., Pink J. R., Sinigaglia F., Stürchler D., Takacs B., Trzeciak A. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J Immunol. 1988 Jan 15;140(2):626–633. [PubMed] [Google Scholar]
  11. Etlinger H. M., Gillessen D., Lahm H. W., Matile H., Schönfeld H. J., Trzeciak A. Use of prior vaccinations for the development of new vaccines. Science. 1990 Jul 27;249(4967):423–425. doi: 10.1126/science.1696030. [DOI] [PubMed] [Google Scholar]
  12. Galelli A., Charlot B. Clonal anergy of memory B cells in epitope-specific regulation. J Immunol. 1990 Oct 15;145(8):2397–2405. [PubMed] [Google Scholar]
  13. Gaur A., Arunan K., Singh O., Talwar G. P. Bypass by an alternate 'carrier' of acquired unresponsiveness to hCG upon repeated immunization with tetanus-conjugated vaccine. Int Immunol. 1990;2(2):151–155. doi: 10.1093/intimm/2.2.151. [DOI] [PubMed] [Google Scholar]
  14. Giannini G., Rappuoli R., Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res. 1984 May 25;12(10):4063–4069. doi: 10.1093/nar/12.10.4063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Granoff D. M., Boies E. G., Munson R. S., Jr Immunogenicity of Haemophilus influenzae type b polysaccharide--diphtheria toxoid conjugate vaccine in adults. J Pediatr. 1984 Jul;105(1):22–27. doi: 10.1016/s0022-3476(84)80350-9. [DOI] [PubMed] [Google Scholar]
  16. Herzenberg L. A., Tokuhisa T. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J Exp Med. 1982 Jun 1;155(6):1730–1740. doi: 10.1084/jem.155.6.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Herzenberg L. A., Tokuhisa T., Hayakawa K. Epitope-specific regulation. Annu Rev Immunol. 1983;1:609–632. doi: 10.1146/annurev.iy.01.040183.003141. [DOI] [PubMed] [Google Scholar]
  18. Leclerc C., Schutze M. P., Deriaud E., Przewlocki G. The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression. J Immunol. 1990 Sep 1;145(5):1343–1349. [PubMed] [Google Scholar]
  19. Lise L. D., Mazier D., Jolivet M., Audibert F., Chedid L., Schlesinger D. Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun. 1987 Nov;55(11):2658–2661. doi: 10.1128/iai.55.11.2658-2661.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Peeters C. C., Tenbergen-Meekes A. M., Evenberg D. E., Poolman J. T., Zegers B. J., Rijkers G. T. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J Immunol. 1991 Jun 15;146(12):4308–4314. [PubMed] [Google Scholar]
  21. Porro M., Saletti M., Nencioni L., Tagliaferri L., Marsili I. Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid. J Infect Dis. 1980 Nov;142(5):716–724. doi: 10.1093/infdis/142.5.716. [DOI] [PubMed] [Google Scholar]
  22. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schneerson R., Robbins J. B., Chu C., Sutton A., Vann W., Vickers J. C., London W. T., Curfman B., Hardegree M. C., Shiloach J. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun. 1984 Sep;45(3):582–591. doi: 10.1128/iai.45.3.582-591.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schneerson R., Robbins J. B., Parke J. C., Jr, Bell C., Schlesselman J. J., Sutton A., Wang Z., Schiffman G., Karpas A., Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 1986 May;52(2):519–528. doi: 10.1128/iai.52.2.519-528.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schutze M. P., Deriaud E., Przewlocki G., LeClerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol. 1989 Apr 15;142(8):2635–2640. [PubMed] [Google Scholar]
  26. Schutze M. P., Leclerc C., Jolivet M., Audibert F., Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. 1985 Oct;135(4):2319–2322. [PubMed] [Google Scholar]
  27. Slack J., Der-Balian G. P., Nahm M., Davie J. M. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med. 1980 Apr 1;151(4):853–862. doi: 10.1084/jem.151.4.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vella P. P., Ellis R. W. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys. Pediatr Res. 1991 Jan;29(1):10–13. doi: 10.1203/00006450-199101000-00003. [DOI] [PubMed] [Google Scholar]
  29. Vogel F. R., Leclerc C., Schutze M. P., Jolivet M., Audibert F., Klein T. W., Chedid L. Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide. Cell Immunol. 1987 Jun;107(1):40–51. doi: 10.1016/0008-8749(87)90264-4. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES